EUVIMEDEUVIMED entdecken
VergleichsstudieOpen Access · CC BY 4.0

Immunotherapy or antiangiogenic therapy plus chemotherapy as first‐line treatment of patients with PD‐L1 (‐) advanced non‐squamous non‐small cell lung cancer in a Chinese cohort

Ruolan Xia, Yanying Li, Ling Yang, Meijuan Huang iD

Cancer Medicine · 2023

DOI: 10.1002/cam4.6101 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Cancer Medicine, 2023. Verfasst von Ruolan Xia und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biotherapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University Chengdu, Chengdu, China. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose For patients with advanced nonsquamous non‐small cell lung cancer (NSCLC), immunotherapy or antiangiogenic therapy combined with pemetrexed and cisplatin/carboplatin have both shown significant efficacy at programmed cell death ligand 1 (PD‐L1) levels of

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsB7-H1 AntigenEast Asian PeopleImmunotherapyRetrospective StudiesAngiogenesis InhibitorsAntineoplastic Agents, Immunological

Stichwörter der Autor:innen

bevacizumabchemotherapyimmunotherapynonsquamous non-small cell lung cancertreatment

Substanzen

B7-H1 AntigenAngiogenesis InhibitorsAntineoplastic Agents, ImmunologicalCD274 protein, human

Autor:innen und Institutionen

  • Department of Biotherapy, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University Chengdu, Chengdu, China.
  • West China School of Medicine, Sichuan University, Chengdu, China.
  • Division of Thoracic Tumor Multimodality Treatment and Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China.

ORCID-Profile: Meijuan Huang

Zitieren

APA

Xia, R., Li, Y., Yang, L., & Huang, M. (2023). Immunotherapy or antiangiogenic therapy plus chemotherapy as first‐line treatment of patients with PD‐L1 (‐) advanced non‐squamous non‐small cell lung cancer in a Chinese cohort. Cancer Medicine. https://doi.org/10.1002/cam4.6101

Vancouver

Xia R, Li Y, Yang L, Huang M. Immunotherapy or antiangiogenic therapy plus chemotherapy as first‐line treatment of patients with PD‐L1 (‐) advanced non‐squamous non‐small cell lung cancer in a Chinese cohort. Cancer Medicine. 2023. doi:10.1002/cam4.6101

BibTeX
@article{Xia2023,
  author = {Xia, Ruolan and Li, Yanying and Yang, Ling and Huang, Meijuan},
  title = {Immunotherapy or antiangiogenic therapy plus chemotherapy as first‐line treatment of patients with PD‐L1 (‐) advanced non‐squamous non‐small cell lung cancer in a Chinese cohort},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.6101}
}
Kostenlos starten →